The validation trial is going to be shorter, sooner and cheaper than I expected. The r&d rebate we get in a few weeks is enough to cover it. great hemorrhagic stroke sensitivity results well above targets and going into the validation trial with a lot of confidence. i think this stock can move very fast when the focus shifts to the financial prospects.
Ann: Algorithms Deliver Excellent Results In EMView Study, page-11
Add to My Watchlist
What is My Watchlist?
